Philadelphia, PANCT07482787Now EnrollingIRB Ready

Epidermolysis Bullosa (EB) Clinical Trial in Philadelphia, PA

Access cutting-edge epidermolysis bullosa (eb) treatment through this phase 3 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Paradigm Therapeutics

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access epidermolysis bullosa (eb) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related epidermolysis bullosa (eb) treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this epidermolysis bullosa (eb) clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Epidermolysis Bullosa (EB) Study in Philadelphia

The upcoming trial is for EB patients is a topically applied whole-body treatment of patients with either Simplex, RDEB or Junctional (nH) ages 1 month to 12 years old at study entry. There are only 4 site visits by patients with minimal assessments over a 2-month period, and patients completing this study will have the ability to continue receiving SD-101-6.0 at home in an open-label extension study. The drug product and placebo require no special preparation or storage conditions (room temperature).

Sponsor: Paradigm Therapeutics

Who Can Participate

Inclusion Criteria

Informed Consent (ICF) form signed by the patient or patient's legal representative. Since all patients with be 12 years old or younger at study entry, signed assent from the patient's legal representative will be required.
Patient (or caretaker) must be willing to comply with all protocol requirements.
Diagnosis of Simplex, Recessive Dystrophic, or JEB-nH EB.
Patient must have 1 target wound (size 10 to 50 cm2).
Patients must be between 28 days to 12 years at study entry
Target wound must be present for 21 days or more.
Patients must have wound burden based on BSA of ≥5% at baseline

Exclusion Criteria

Patients who do not meet the entry criteria outlined above.
Selected target wound cannot have clinical evidence of local infection.
Use of any investigational drug or approved EB therapy within 30 days before enrollment.
Use of immunotherapy or cytotoxic chemotherapy within 60 days before enrollment.
Use of systemic or topical steroidal therapy within 30 days before enrollment. (Inhaled steroids and ophthalmic drops containing steroids are allowed)
Use of systemic antibiotics within 7 days before enrollment.
Current or former malignancy.
Participant is one of the following:
Not of childbearing potential (premenarchal or male/not in possession of a uterus).
If of childbearing potential, is nonpregnant (negative urine pregnancy test results at Screening), nonlactating, and practicing 1 of the following medically acceptable methods of birth control:
Abstinence from heterosexual intercourse as a lifestyle choice.
Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the participant's usual menstrual cycle period) before product administration.
Intrauterine device. If male, is willing to use a highly effective method of contraception throughout the study period.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT07482787) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Epidermolysis Bullosa (EB) Treatment Options in Philadelphia, PA

If you're searching for epidermolysis bullosa (eb) treatment options in Philadelphia, PA, this clinical trial (NCT07482787) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced epidermolysis bullosa (eb) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all epidermolysis bullosa (eb) clinical trials near you to find additional studies recruiting in your area.

More Sleep Apnea Trials in Philadelphia, PA

See all sleep apnea clinical trials recruiting in Philadelphia — not just this study.

Browse Sleep Apnea Trials in Philadelphia →

Browse More Trials by Condition

Sleep Apnea TrialsAll Conditions →

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA